NOT-OD-24-146: Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health is sponsored by National Heart, Lung, and Blood Institute (NHLBI) (through NIH). This Notice of Special Interest (NOSI) encourages applications for research that focuses on improving adherence to treatment and prevention regimens and the maintenance of health behaviors.

Expired NOT-OD-24-146: Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health This notice has expired. Check the NIH Guide for active opportunities and notices.

Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health First Available Due Date: New Date September 9, 2025 (Prior Date Jan 20, 2024 - Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required).

See PAR-24-084 Jan 18, 2024 - Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional). See PAR-24-122 Dec 21, 2023 - Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required).

See PAR-24-086 Dec 21, 2023 - Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required). See PAR-24-090 Dec 21, 2023 - Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required).

See PAR-24-087 Dec 21, 2023 - NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required). See PAR-24-083 Dec 15, 2023 - Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required). See PAR-24-072 Dec 6, 2023 - Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional).

See PAR-23-318 Sept 26, 2023 - Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional). See PAR-23-309 July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed). See NOFO PA-23-230 .

July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required). See NOFO PA-23-231 . July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed).

See NOFO PA-23-232 . July 12, 2023 - PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required). See NOFO PA-23-233 May 10, 2023 – Dissemination and Implementation Research in Health (R21 Clinical Trial Optional).

See PAR-22-109 May 10, 2023 – Dissemination and Implementation Research in Health (R01 Clinical Trial Optional). See PAR-22-105 . Feb 2, 2023 - NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional).

See PAR-23-111 . Jan 31, 2023 - Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional). See PAR-23-112 Jan 13, 2023 - Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed).

See PAR-23-105 Jan 12, 2023 - Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed). See RFA-AG-24-001 Jan 11, 2023 - Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional). See PAR-23-060 Jan 11, 2023 - Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional).

See PAR-23-061 Jan 11, 2023 - Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional). See PAR-23-062 Jan 8, 2023 - Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial Optional). See PAR-24-064 Jan 6, 2023 – Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed).

See PAR-23-095 . Dec 23, 2022 - Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) PAR-23-081 Dec 23, 2022 - Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional).

See PAR-23-083 Dec 14, 2022 - National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional). See PAR-23-059 Dec 5, 2022 - NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional).

See PAR-23-058 Sept 9, 2022 - NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional). See PAR-22-230 Sept 9, 2022 - NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional). See PAR-22-231 June 21, 2022 - Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional).

See PAS-22-196 June 21, 2022 - Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional). See PAS-22-197 May 9, 2022 - Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional). See PAR-22-182 May 9, 2022 - Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional).

See PAR-22-183 Mar 31, 2022 - Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional). See PAR-22-145 Mar 10, 2022 - NIA Program Project Applications (P01 Clinical Trial Optional). See PAR-22-130 Oct 12, 2021 - Exploratory Grants in Cancer Control (R21 Clinical Trial Optional).

See PAR-21-341 Mar 3, 2021 - Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required). See PAR-21-131 Mar 2, 2021 - Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required). See PAR-21-130 Nov 24, 2020 - Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required).

See PAR-20-309 May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required). See PA-20-194 May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed). See PA-20-195 May 7, 2020 - NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required).

See PA-20-196 May 5, 2020 - NIH Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required). See PA-20-184 May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed). See PA-20-185 May 5, 2020 - NIH Research Project Grant (Parent R01 Clinical Trial Required).

See PA-20-183 Office of Behavioral and Social Sciences Research ( OBSSR ) Office of AIDS Research ( OAR ) National Eye Institute ( NEI ) National Heart, Lung, and Blood Institute ( NHLBI ) National Institute on Drug Abuse ( NIDA ) National Institute of Mental Health ( NIMH ) National Institute of Nursing Research ( NINR ) National Institute on Minority Health and Health Disparities ( NIMHD ) National Center for Complementary and Integrative Health ( NCCIH ) National Cancer Institute ( NCI ) All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers.

The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention ( ODP ) Office of Research on Women's Health ( ORWH ) This Notice of Special Interest (NOSI) is being re-issued by the NIH Adherence Network through the Office of Behavioral and Social Sciences Research (OBSSR), with participation from multiple NIH Institutes, Centers, and Offices.

This NOSI calls for research grant applications that address adherence to recommended treatment and prevention regimens or maintenance of behaviors to promote positive health outcomes (collectively referred to as health behaviors). Applications may address health behavior initiation, execution, and/or persistence through mechanistic studies, efficacy trials, or implementation research.

Descriptive studies and intervention research may address relevant determinants at one or more levels of ecologic influence, including the individual, caregiver/family, provider, healthcare system, and community levels. Approaches designed to reduce health disparities and improve equitable health outcomes are strongly encouraged. The specific research interests of participating NIH Institutes, Centers, and Offices are detailed below.

Increased adherence to recommended treatment and prevention regimens is an area of the behavioral and social sciences that promises substantial improvements in individual and public health, as well as savings in healthcare costs. Poor adherence to recommended healthcare regimens is common across many chronic health conditions and populations.

This includes many recommended prevention, screening, treatment, monitoring, and health behavior regimens. Current concepts of adherence are multidimensional.

Adherence to a recommended healthcare regimen (e.g., taking a medication, following a diet, making dietary changes) comprises three components: initiation (starting the regimen behaviors), execution (enacting the regimen behaviors with fidelity), and persistence (sustaining the behaviors over time).

Each component of adherence may present unique challenges and determinants, and each may require distinct behavioral and social interventions that rely on various mechanisms of action. A particular challenge has been the long-term maintenance of health behaviors, since many people have difficulty turning a newly initiated health behavior into a consistent practice.

Behavioral maintenance involves consistently performing a newly established health behavior to specified criteria over time and across contexts. The behavior may be one of omission (e.g., not smoking) or commission (e.g., flossing teeth).

Maintaining health behaviors is a dynamic process in which people may cycle in and out of the behavior before reaching a regular practice and/or steady state, and the criteria for maintenance may be situational depending on the health outcome.

The dynamic nature of adherence and long-term behavioral maintenance underscores the importance of improved monitoring of health behaviors and associated determinants to prompt the timely delivery of support interventions when needed. The determinants of adherence and long-term behavioral maintenance span a broad ecologic spectrum.

These range from characteristics of the illness and the healthcare or behavior regimen to individual and interpersonal influences. They also include larger structural influences like healthcare coverage, economic inequality, and structural racism.

These multilevel determinants invite a range of possible interventions that address individuals, families, caregivers, health care providers, health care system factors, and/or communities to facilitate adherence and behavioral maintenance. Developing effective interventions requires careful specification and assessment of their mechanisms of action.

Multilevel approaches to improve adherence to treatment and preventive regimens and to achieve long-term behavioral maintenance are particularly important for addressing inequities in health outcomes. Marginalized and minoritized communities may lack access to healthcare and resources that support adherence and behavioral maintenance.

In addition, they may experience barriers related to prejudice, discrimination, and intersectional stigma in healthcare settings. Achieving greater health equity across NIH-defined health disparity populations may therefore require interventions that not only address marginalized and minoritized communities, but also improve healthcare delivery itself.

Research to address challenges and inequities in adherence and behavioral maintenance will continue to benefit from close attention to scientific rigor. Studies will be expected to clearly define their outcomes, i.e., specifying the desired behavior change (e.g., initiation or maintenance), complement self-reported measures with objective assessments of behavior, and address intervention mechanisms of action.

Grounding research and intervention in behavioral and social science theory will help specify intervention targets and mechanisms of action. Intervention studies are encouraged to consider enrolling individuals with documented challenges in adherence or behavioral maintenance to avoid ceiling effects that may prohibit a determination of intervention efficacy.

Implementation studies designed to advance the adoption and use of evidenced-based interventions are encouraged. The objective of this NOSI is to encourage research grant applications that address adherence to recommended treatment and prevention regimens and maintenance of behaviors to promote health outcomes.

Applications may address health behavior initiation, execution, and/or maintenance through mechanistic studies, efficacy trials, or implementation research. Descriptive and intervention research may address relevant determinants at one or more levels of ecologic influence, including the patient, caregiver/family, provider, healthcare system, and community levels.

Approaches designed to reduce health disparities and improve equitable health outcomes are strongly encouraged. Research projects that could be addressed in response to this NOSI include, but are not limited to, the following topics. Further priorities specific to participating Institutes, Centers, and Offices subsequently follow.

Research to advance novel tools or improve implementation of existing approaches to monitor adherence and long-term behavioral maintenance to facilitate delivery of timely interventions. Research that identifies the mechanisms of action that support behavior change to improve adherence and maintenance.

Research to understand and address individual, social, and structural determinants of health contributing to inequities in adherence and associated health outcomes among NIH-designated health disparity populations, including racial and ethnic minority groups, sexual and gender minority (SGM) groups, people with disabilities, people with lower socioeconomic status (SES), and underserved rural communities.

Research examining interventions designed to optimize adherence and maintenance of health behaviors through caregivers, peers, or social support networks. Studies of adherence-promoting behavior maintenance strategies that are delivered through technology tools, such as mobile health apps, mobile medical devices, and electronic health records.

Research testing the efficacy of interventions delivered at the healthcare provider or system-level that may facilitate patient adherence and maintenance of health behaviors. Multilevel and multicomponent interventions (e.g., at the individual, healthcare provider, and community level) that improve adherence and behavioral maintenance.

IC Specific Application and Submission Information: National Center for Complementary and Integrative Health ( NCCIH ) NCCIH is interested in research on the use of complementary and integrative health approaches to enhance adherence to treatment or prevention regimens and maintenance of behaviors to promote or restore health, prevent disease, as well as foster well-being, resilience, or symptom management.

NCCIH is also interested in research to enhance adherence and maintenance of behaviors with complementary and integrative health approaches. Please see https://www. nccih.

nih. gov/about/strategic-plans-and-reports or a full description of NCCIH’s strategic priorities. For this NOSI, complementary and integrative health approaches of interest include those with physical and/or psychological therapeutic inputs, often called mind and body approaches (e.g., acupuncture, yoga, tai chi, qi gong, meditation, hypnosis, music-based interventions, art therapy, spinal and/or joint manipulation, or massage therapy).

Also of interest are multi-component interventions such as a combination of two or more complementary health approaches or integrated approaches to care in which a complementary health approach is used in combination with standard care (e.g., mindfulness or yoga to improve adherence to conventional therapeutics).

NCCIH will not support applications through this NOSI with a primary outcome of assessing the efficacy or effectiveness of the complementary and integrative approach on a clinical outcome (see https://nccih. nih. gov/grants/funding/clinicaltrials ).

Investigators are strongly encouraged to discuss their plans with NCCIH program staff prior to submitting their application. National Cancer Institute ( NCI ) NCI seeks research that will improve adherence to recommended cancer prevention and treatment regimens to reduce cancer risk, improve treatment outcomes, and lower cancer-related morbidity, mortality, and disability.

Research aimed at initiation, implementation and persistence of adherence-related behaviors is of interest. Multi-level studies and research aimed at high-risk, vulnerable, or underserved populations are encouraged.

Priority topics include but are not limited to: Improving adherence to lifestyle recommendations related to cancer incidence and outcomes, including diet, physical activity/sedentary behaviors, energy balance and obesity, UV protection, alcohol and tobacco use, and sleep. Improving adherence to recommended cancer prevention regimens, cancer screening tests, treatment regimens, maintenance therapy, and follow-up care.

Improving adherence to oral cancer therapies, with an emphasis on immunotherapy and molecularly targeted therapies. Understanding and addressing the effects of polypharmacy on symptoms and treatment adherence. Developing system-level approaches to improve adherence, including research that addresses healthcare providers, healthcare team interactions, and aspects of care delivery.

Testing personalized approaches to improve adherence, including targeted and tailored adherence interventions and messages. Developing novel interventions to improve adherence based on basic behavioral and social science findings (see ORBIT model for behavioral treatment development).

Identifying optimal approaches for disseminating and implementing evidence-based adherence interventions within systems of care and home, school, workplace and community settings. National Eye Institute ( NEI ) NEI seeks research on adherence to interventions/treatments in the context of vision health and impairment.

Areas of interest include but are not limited to adherence to low vision rehabilitation training, myopia prevention/treatment, pediatric amblyopia therapies, and glaucoma treatment regimens. In addition, improving adherence to prevention efforts (e.g., eye care screening) or follow-up eye examinations and development of novel personalized approaches and/or technological tools (e.g., mobile health) to enhance adherence are welcome.

In the context of this NOSI, clinical trial studies that are greater than minimal risk will not be supported. (Minimal risk is defined as the probability and magnitude of harm or discomfort anticipated in the research are not greater in and of themselves than those ordinarily encountered in daily life or during the performance of routine physical or psychological examinations or tests.)

Investigators are strongly encouraged to discuss their plans with NEI program staff prior to submitting their application. National Heart, Lung, and Blood Institute ( NHLBI ) The National Heart, Lung, and Blood Institute (NHLBI) is interested in adherence research and product development relevant to its Strategic Vision ( https://www. nhlbi.

nih. gov/about/strategic-vision ), to promote and maintain heart, lung, blood, and sleep (HLBS) health.

For this NOSI, NLHBI will support research across the translational spectrum, including observational and mechanistic studies as well as pilot or full-scale efficacy and effectiveness trials, for the development and evaluation of novel interventions to improve adherence to behavioral or pharmacologic regimens that promote and maintain heart, lung, blood, and sleep health.

NHLBI is also interested in supporting applications that include qualitative, quantitative, and mixed-methods research to understand and address the multi-level determinants of adherence across social and economic contextual factors.

NHLBI recognizes the importance of research on interventions that focus on different target populations across the spectrum, from patients and family caregivers to healthcare providers and structural components of healthcare systems. Implementation research to identify and evaluate strategies to promote adoption of public health or clinical guidelines and evidence-based interventions is encouraged.

NHLBI is interested in supporting adherence research across the stages of behavioral change, especially research focused on understanding and facilitating maintenance of adherence post-intervention and even beyond the project period. Innovative uses of advances in behavioral science, mobile and connected health technology, healthcare informatics, and AI/ML technology, are encouraged.

Regardless of the target population or the type of intervention, NHLBI encourages applications that integrate the patient perspective into intervention and implementation design, product development, and identification of patient-centered outcomes.

NHLBI remains strongly committed to research that aims to mitigate adherence-related health disparities and improve health outcomes for high-risk communities, including NIH-designated populations that experience health disparities . Applications proposing clinical trials may require Milestone Accrual Plans and/or other performance milestones prior to award (see https://www. nhlbi.

nih. gov/grants-and-training/policies-and-guidelines/accrual-of-human-subjects-milestones-policy ). Investigators are strongly encouraged to discuss their plans with NHLBI program staff prior to submitting their application.

National Institute on Aging ( NIA ) NIA seeks research on interventions to promote adherence to medical and behavioral regimens in mid- to late life aimed at preventing age-related diseases and cognitive decline and promoting healthy and adaptive aging.

Aging itself remains the most significant risk factor for many chronic diseases and conditions, including Alzheimer’s disease and related forms of dementia (AD/ADRD), most types of cancer, many types of heart disease, osteoporosis and hip fracture, kidney failure, and diabetes.

NIA applications under this NOFO are expected to articulate their research aims using the NIH Stage Model framework, identifying the Stage(s) of research proposed as defined by the NIH Stage Model.

In addition, applications are encouraged to apply the experimental medicine approach, i.e. articulate or test a hypothesis to identify an intervention’s principles/mechanism(s) of action, as described by the NIH Science of Behavior Change Common Fund Program .

Areas of interest include those that leverage current understanding of behavioral science, psychology of aging, or social and environmental contexts relevant to aging to promote adherence to exercise, healthful eating, prescribed medications, stress-reducing and/or positive affect inducing behaviors, and medical regimens.

Of particular interest is the development of scalable principle-driven interventions that are highly relevant to the needs and capacities of individuals as they age; interventions that incorporate behavioral economic principles and/or technological innovations; interventions to prevent, treat, or improve care for individuals living with AD/ADRD; interventions with a geriatric focus on multiple chronic conditions that may involve polypharmacy; and interventions promoting adherence to screening, vaccination, and other preventive measures in older adults.

National Institute on Drug Abuse ( NIDA ) NIDA is interested in research on the development of optimal behavioral strategies to promote adherence to medication-based and other substance use disorder (SUD) treatments.

Applications are encouraged for studies that include, but are not limited to: improvements in drug abuse treatment adherence interventions for use in primary care; technologies to boost effects and increase efficiency of adherence interventions, and; interventions to promote adherence to HIV medications (including PrEP).

National Institute of Mental Health ( NIMH ) National Institute on Minority Health and Health Disparities ( NIMHD ) NIMHD is interested in supporting research and interventions considering determinants from more than one domain or level of influence (see NIMHD Research Framework ). NIMHD is particularly interested in research on adherence that supports the NIMHD. nih.

gov/about/strategic-plan/. Intervention design should be based on theories from minority health and health disparities science.

Research must focus on one or NIH-designated health disparity population (African American or Black, Hispanic or Latino, American Indian or Alaska Native, Asian, Middle Eastern or North African, Native Hawaiians or Pacific Islanders, socioeconomically disadvantaged populations, underserved rural populations, sexual and gender minority populations, and people living with disabilities).

Applications may include but are not limited to multi-disciplinary etiologic and intervention research projects in community settings that advance the understanding of the mechanisms, pathways, and processes related to adherence to health promotion behaviors (e.g., healthy eating, physical activity, safe infant sleep practices, etc.), preventive screening recommendations, medication or other medical treatment regimens, and/or chronic disease self-management strategies.

Research may propose using available secondary data, health system data and/or collection of primary data. National Institute of Nursing Research ( NINR ) The National Institute of Nursing Research (NINR) supports research aligned with our mission and strategic priorities, conducted by scientists from any discipline.

NINR discovers solutions to health challenges through the lenses of health equity, social determinants of health, population and community health, prevention and health promotion, and systems and models of care.

Drawing on the strengths of nursing’s holistic, contextualized perspective, core values, and broad reach, NINR funds multilevel and cross-sectoral research that examines the factors that impact health across the many settings in which nurses practice, including homes, schools, workplaces, clinics, justice settings, and the community.

Office of AIDS Research ( OAR ) OAR, as part of the NIH Office of the Director (OD), is interested in research to address HIV-related adherence across prevention, treatment, and care. This includes adherence as it applies to recommended treatment and prevention regimens and/or maintenance of behaviors to optimize health outcomes. This includes factors across the spectrum of HIV-related health behaviors.

Because the NIH OAR does not award grants, applications must also be relevant to the objectives of at least one of the participating NIH Institutes and Centers (IC) listed in this announcement. Please contact the relevant IC program contacts listed for questions related to funding.

Office of Disease Prevention ( ODP ) Office of Research on Women's Health ( ORWH ) Application and Submission Information This NOSI applies to due dates on or after 7/15/2024 and subsequent receipt dates through 7/14/2027. Applicants must select the IC and associated NOFO to use for submission of an application in response to this NOSI. The selection must align with the IC requirements listed to be considered responsive to that NOFO.

Non-responsive applications will be withdrawn from consideration for this initiative. In addition, applicants using NIH Parent Announcements (listed below) will be assigned to those ICs on this NOSI that have indicated those NOFOs are acceptable and based on usual application-IC assignment practices.

Research Project Grant (Parent R01 Clinical Trial Required) NCCIH, NEI, NHLBI, NIDA, NIMHD Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) NCCIH, NEI, NHLBI, NCI, NIMHD NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required) PHS 2023-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) NCCIH, NCI, NEI, NHLBI, NIMHD PHS 2023-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) NCCIH, NCI, NEI, NHLBI, NIMHD PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) NCCIH, NCI, NEI, NHLBI, NIMHD PHS 2023-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) NCCIH, NCI, NEI, NHLBI, NIMHD Dissemination and Implementation Research in Health (R01 Clinical Trial Optional) Dissemination and Implementation Research in Health (R21 Clinical Trial Optional) Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required) PAR-21-341 Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) 10/12/2021 NCI NIA Program Project Applications (P01 Clinical Trial Optional) Leveraging Health Information Technology (Health IT) to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional) Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional) Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional) Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional) Advancing Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R41/R42 Clinical Trial Optional) NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R01 Clinical Trial Optional) NINR Areas of Emphasis for Research to Optimize Health and Advance Health Equity (R21 Clinical Trial Optional) NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional) National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional) Formative and Pilot Intervention Research to Optimize HIV Prevention and Care Continuum Outcomes (R34 Clinical Trial Optional) Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R21 Clinical Trial Optional) Innovations to Optimize HIV Prevention and Care Continuum Outcomes (R01 Clinical Trial Optional) Early and Late Stage Clinical Trials for the Spectrum of Alzheimer’s Disease/Alzheimer’s Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) Pilot Studies for the Spectrum of Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional) Innovative Mental Health Services Research Not Involving Clinical Trials (R01 Clinical Trials Not Allowed) Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 - Clinical Trial Optional) Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial Optional) Health and Health Care Disparities Among Persons Living with Disabilities (R01 - Clinical Trials Optional) Mobile Health: Technology and Outcomes in Low and Middle Income Countries (R21/R33 - Clinical Trial Optional) Alzheimer's Disease Research Centers (P30 Clinical Trial Not Allowed) Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required) Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required) Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required) Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required) Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required) Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) All instructions in the SF424 (R&R) Application Guide and the notice of funding opportunity used for submission must be followed, with the following additions: For funding consideration, applicants must include “NOT-OD-24-146” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form.

Applications without this information in box 4B will not be considered for this initiative Investigators planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with Program staff/Scientific Contacts listed on this NOSI well in advance of the application receipt date to better determine appropriateness and interest of the relevant Institute.

Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative. Please direct all inquiries to the Scientific/Research, Peer Review, and Financial/Grants Management contacts in Section VII of the listed notice of funding opportunity. Scientific/Research Contact(s) Jennifer N.

Baumgartner, Ph. D.

National Center for Complementary and Integrative Health (NCCIH) National Cancer Institute (NCI) National Eye Institute (NEI) Laurie Friedman Donze, PhD National Heart, Lung, and Blood Institute (NHLBI) National Institute on Aging (NIA) E-mail: [email protected] NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) E-mail: [email protected] National Institute of Mental Health (NIMH) National Institute of Mental Health (NIMH) Priscah Mujuru DrPH, MPH, RN National Institute on Minority Health and Health Disparities (NIMHD) E-mail: [email protected] Karen Huss, PhD, RN, ANP-BC, FAAN, FAAAAI, FAHA National Institute of Nursing Research (NINR) OBSSR, OAR, ODP, and ORWH do not directly award grants but may provide co-funding.

Please contact one of the IC program contacts listed above for questions regarding funding interest.

Office of Behavioral and Social Sciences Research (OBSSR) NIH Office of AIDS Research (OAR) Office of Disease Prevention (ODP) E-mail: [email protected] Balkissa Ouattara, MD, PhD, MPH Office of Research on Women’s Health (ORWH) Examine your eRA Commons account for review assignment and contact information (information appears two weeks after the submission due date).

Financial/Grants Management Contact(s) National Center for Complementary and Integrative Health (NCCIH) National Cancer Institute (NCI) NATIONAL EYE INSTITUTE (NEI) E-mail: [email protected] NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) E-mail: [email protected] National Institute on Aging (NIA) E-mail: [email protected] NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) E-mail: [email protected] National Institute of Mental Health (NIMH) NIMHD - NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES E-mail: [email protected] National Institute of Nursing Research (NINR) Weekly TOC for this Announcement NIH...

Turning Discovery Into Health